Foley & Lardner LLP
Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of a recombinant modified vaccinia Ankara (MVA) virus comprising an MVA harboring a human Fms-like tyrosine kinase 3 ligand (hFlt3L) (MVA-hFtl3L). The foregoing vaccinia Ankara (MVA) virus can be delivered to tumor cells of a subject afflicted with a malignant solid tumor, to treat the tumor. In a related aspect, the present disclosure concerns a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MV At.E3L) modified to express human Fms-like 5 tyrosine kinase 3 ligand (hFlt3L) isolated, suitable for use as an immunotherapeutic agent against a malignant solid tumor.
MEMORIAL SLOAN KETTERING CANCER CENTER
A C C A A A C A C C C A C C C A
A61P C12N C07K A61K A61K A61K C12N A61K C07K C07K C12N A61K C12N C07K C12N A61K
inventional additional inventional inventional inventional additional additional inventional inventional additional additional inventional inventional inventional additional additional
Peihong Stewart Taha Weiyi Jedd Liang Ning
Dai Shuman Merghoub Wang Wolchok Deng Yang